Trial Profile
VIldagliptin as an ischemic PERconditioning mimetic agent in Acute Myocardial Infarction – A single centre, randomized, parallel-group, double-blind clinical trial, for assessing the effectiveness of pharmacological myocardial conditioning in STEMI using vildagliptin.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Apr 2015
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms VIPER-AMI
- 20 Feb 2015 New trial record